This is not the most recent version of the article. View current version (25 JUL 2013)

Intervention Review

Oxygen therapy for cystic fibrosis

  1. Heather E Elphick1,*,
  2. George Mallory2

Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group

Published Online: 21 JAN 2009

Assessed as up-to-date: 17 JAN 2011

DOI: 10.1002/14651858.CD003884.pub3

How to Cite

Elphick HE, Mallory G. Oxygen therapy for cystic fibrosis. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD003884. DOI: 10.1002/14651858.CD003884.pub3.

Author Information

  1. 1

    Sheffield Children's Hospital, Respiratory Unit, Sheffield, UK

  2. 2

    Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, USA

*Heather E Elphick, Respiratory Unit, Sheffield Children's Hospital, Western Bank, Sheffield, S10 2TH, UK. Heather.Elphick@sch.nhs.uk. H.Elphick@sheffield.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 JAN 2009

SEARCH

This is not the most recent version of the article. View current version (25 JUL 2013)

 

Abstract

  1. Top of page
  2. Abstract
  3. Plain language summary

Background

The most serious complications of cystic fibrosis (CF) relate to respiratory insufficiency. Oxygen supplementation therapy has long been a standard of care for individuals with chronic lung diseases associated with hypoxemia. Physicians commonly prescribe oxygen therapy for people with CF when hypoxemia occurs. However, it is unclear if empiric evidence is available to provide indications for this therapy with its financial costs and often profound impact on lifestyle.

Objectives

To assess whether oxygen therapy improves the longevity or quality of life of individuals with CF.

Search methods

We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register, comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.

Latest search of Group's Trials Register: 09 September 2010.

Selection criteria

Randomized or quasi-randomized controlled trials comparing oxygen, administered at any concentration, by any route, in people with documented CF for any time period.

Data collection and analysis

Authors independently assessed the risk of bias for included studies and extracted data.

Main results

This review includes 11 published studies (172 participants); only one examined long-term oxygen therapy (28 participants). There was no statistically significant improvement in survival, lung, or cardiac health. There was an improvement in regular attendance at school or work in those receiving oxygen therapy at 6 and 12 months. Four studies examined the effect of oxygen supplementation during sleep by polysomnography. Although oxygenation improved, mild hypercapnia was noted. Participants fell asleep quicker and spent a reduced percentage of total sleep time in rapid eye movement sleep, but there were no demonstrable improvements in qualitative sleep parameters. Six studies evaluated oxygen supplementation during exercise. Again, oxygenation improved, but mild hypercapnia resulted. Participants receiving oxygen therapy were able to exercise for a significantly longer duration during exercise. Other exercise parameters were not altered by the use of oxygen.

Authors' conclusions

There are no published data to guide the prescription of chronic oxygen supplementation to people with advanced lung disease due to CF. Short-term oxygen therapy during sleep and exercise improves oxygenation but is associated with modest and probably clinically inconsequential hypercapnia. There are improvements in exercise duration, time to fall asleep and regular attendance at school or work. There is a need for larger, well-designed clinical trials to assess the benefits of long-term oxygen therapy in people with CF administered continuously or during exercise or sleep or both.

 

Plain language summary

  1. Top of page
  2. Abstract
  3. Plain language summary

Additional oxygen in the treatment of cystic fibrosis

People with cystic fibrosis (CF) suffer from breathing problems. Giving additional oxygen has long been a standard of care for people with chronic lung diseases. It is common for doctors to prescribe this treatment for people with CF when there is not enough oxygen in their blood. We looked for evidence that this treatment improves the length and quality of life for people with CF. We found eleven studies with 172 participants to include in the review. All studies compared low-flow oxygen to room air. Ten of the studies were short-term. Four of the studies looked at giving additional oxygen at night. At night, oxygen levels rose during both rapid eye movement (REM) sleep and non-REM sleep in those people breathing low-flow oxygen. Participants breathing oxygen at night also spent less time in REM sleep and took less time to fall asleep. Six of the studies looked at the effect of extra oxygen on exercise. The levels of oxygen and carbon dioxide in the blood of participants increased during or after exercise when they breathed in low-flow oxygen. People were able to exercise for longer if they breathed in low-flow oxygen. There was more regular attendance at school or work in those receiving long-term oxygen. There is little evidence to support or oppose the long-term use of oxygen therapy in people with advanced CF lung disease. In the short term, treatment has shown some improvement in blood oxygen levels in people with CF during sleep and exercise. This increase in oxygen also came with an increase in carbon dioxide levels, which is probably not clinically important. However, caution needs to be exercised in those with advanced lung disease where this may require further monitoring.There should be research into the effects of long-term oxygen treatment on sleep quality and exercise in people with CF.